Skip to content
2000
image of Endothelin: A Potential Universal Systemic Biomarker

Abstract

Background

Endothelins is a family of vasoconstrictive peptides known for their high potency. They are mainly synthesized and secreted by the endothelial cells lining the blood vessels in response to various stimuli. Their main physiological role is the regulation of vascular tone, affecting blood pressure and tissue perfusion.

Objective

The aim of this review was to evaluate the importance of Endothelin-1 (ET-1) plasma levels as a marker in diagnosis, disease burden, or development, due to its vascular effects.

Methods

Data was collected and grouped, from several studies in different organ systems, during the last thirty years, were collected. A statistical analysis was performed to reveal any similarities and differences among them.

Results

ET-1 was found to be increased in arterial and pulmonary hypertension. Plasma ET-1 was elevated in patients with heart failure, autoimmune disease, chronic kidney disease, and liver failure. In all these cases, ET-1 was increased at least twice the maximum of normal plasma concentration in healthy subjects, in a similar pattern, independently of the disease background. More importantly, plasma ET-I levels increased even more according to the severity of the disease, not necessarily in a linear manner.

Discussion

Plasma ET-1 levels appears to increase whenever a disorder or dysfunction occurs in kidney, heart, lungs, liver and pancreas. Since, remission is followed by a reduction in the already elevated levels, plasma ET-1 emerges to be an important diagnostic molecule.

Conclusion

Endothelin-1 appears to increase similarly across various pathological conditions, making it a potential biomarker for overall human physiological status.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673377544250714073536
2025-09-30
2025-11-04

  • From This Site

    /content/journals/cmc/10.2174/0109298673377544250714073536
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Furchgott R.F. Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980 288 5789 373 376 10.1038/288373a0 6253831
    [Google Scholar]
  2. Yanagisawa M. Kurihara H. Kimura S. Tomobe Y. Kobayashi M. Mitsui Y. Yazaki Y. Goto K. Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988 332 6163 411 415 10.1038/332411a0 2451132
    [Google Scholar]
  3. Masashi Y. Tomoh M. Molecular biology and biochemistry of the endothelins. Trends Pharmacol. Sci. 1989 10 9 374 378 10.1016/0165‑6147(89)90011‑4 2690429
    [Google Scholar]
  4. Haque S. Welch H. Loizidou M. Handbook of biologically active peptides. 2nd Ed Elsevier 2013 512 518
    [Google Scholar]
  5. Haryono A. Ramadhiani R. Ryanto G.R.T. Emoto N. Endothelin and the cardiovascular system: The long journey and where we are going. Biology 2022 11 5 759 10.3390/biology11050759 35625487
    [Google Scholar]
  6. Kohan D.E. Barton M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int. 2014 86 5 896 904 10.1038/ki.2014.143 24805108
    [Google Scholar]
  7. Schiffrin E. L. Pollock D. M. Endothelin system in hypertension and chronic kidney disease. Hypertension 2024 81 4 691 701 10.1161/HYPERTENSIONAHA.123.21716
    [Google Scholar]
  8. Liu C. Chen J. Gao Y. Deng B. Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane. Libr. 2021 2021 3 CD004434 10.1002/14651858.CD004434.pub6 33765691
    [Google Scholar]
  9. Barton M. Yanagisawa M. Endothelin: 30 Years from discovery to therapy. Hypertension 2019 74 6 1232 1265 10.1161/HYPERTENSIONAHA.119.12105 31679425
    [Google Scholar]
  10. Banecki K.M.R.M. Dora K.A. Endothelin-1 in health and disease. Int. J. Mol. Sci. 2023 24 14 11295 10.3390/ijms241411295 37511055
    [Google Scholar]
  11. Miyamori I. Takeda Y. Yoneda T. Takeda R. Endothelin-1 release from mesenteric arteries of spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 1991 17 Suppl. 7 S408 S410 10.1097/00005344‑199100177‑00115 1725394
    [Google Scholar]
  12. Larivière R. Thibault G. Schiffrin E.L. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension 1993 21 3 294 300 10.1161/01.HYP.21.3.294 8478038
    [Google Scholar]
  13. Tønnessen T. Giaid A. Saleh D. Naess P.A. Yanagisawa M. Christensen G. Increased in vivo expression and production of endothelin-1 by porcine cardiomyocytes subjected to ischemia. Circ. Res. 1995 76 5 767 772 10.1161/01.RES.76.5.767 7728993
    [Google Scholar]
  14. Nassar G.M. Badr K.F. Endothelin in kidney diseases. Curr. Opin. Nephrol. Hypertens. 1994 3 1 86 91 10.1097/00041552‑199401000‑00012 7850416
    [Google Scholar]
  15. Vlachojannis J. Tsakas S. Petropoulou C. Kurz P. Increased renal excretion of endothelin-1 in nephrotic patients. Nephrol. Dial. Transplant. 1997 12 3 470 473 10.1093/ndt/12.3.470 9075126
    [Google Scholar]
  16. Ito H. Endothelins and cardiac hypertrophy. Life Sci. 1997 61 6 585 593 10.1016/S0024‑3205(97)00105‑7 9250714
    [Google Scholar]
  17. Jankowich M. Choudhary G. Endothelin-1 levels and cardiovascular events. Trends Cardiovasc. Med. 2020 30 1 1 8 10.1016/j.tcm.2019.01.007 30765295
    [Google Scholar]
  18. Abraham G.R. Kuc R.E. Althage M. Greasley P.J. Ambery P. Maguire J.J. Wilkinson I.B. Hoole S.P. Cheriyan J. Davenport A.P. Endothelin-1 is increased in the plasma of patients hospitalised with COVID-19. J. Mol. Cell. Cardiol. 2022 167 92 96 10.1016/j.yjmcc.2022.03.007 35339512
    [Google Scholar]
  19. Møller S. Emmeluth C. Henriksen J.H. Elevated circulating plasma endothelin-1 concentrations in cirrhosis. J. Hepatol. 1993 19 2 285 290 10.1016/S0168‑8278(05)80584‑7 8301063
    [Google Scholar]
  20. Chen H.C. Guh J.Y. Chang J.M. Tsai J.C. Hwang S.J. Lai Y.H. Plasma and urinary endothelin-1 in focal segmental glomerulosclerosis. J. Clin. Lab. Anal. 2001 15 2 59 63 10.1002/jcla.2 11291106
    [Google Scholar]
  21. Yeh J.L. Hsu J.H. Dai Z.K. Liou S.F. Chen I.J. Wu J.R. Increased circulating big endothelin-1, endothelin-1 and atrial natriuretic peptide in infants and children with heart failure secondary to congenital heart disease. Int. J. Cardiol. 2005 104 1 15 20 10.1016/j.ijcard.2004.09.010 16055212
    [Google Scholar]
  22. Cellini M. Strobbe E. Gizzi C. Balducci N. Toschi P.G. Campos E.C. Endothelin-1 plasma levels and vascular endothelial dysfunction in primary open angle glaucoma. Life Sci. 2012 91 13-14 699 702 10.1016/j.lfs.2012.02.013 22406080
    [Google Scholar]
  23. Bossard M. Pumpol K. van der Lely S. Aeschbacher S. Schoen T. Krisai P. Lam T. Todd J. Estis J. Risch M. Risch L. Conen D. Plasma endothelin-1 and cardiovascular risk among young and healthy adults. Atherosclerosis 2015 239 1 186 191 10.1016/j.atherosclerosis.2014.12.061 25617859
    [Google Scholar]
  24. Gu X. Li H. Zhu X. Gu H. Chen J. Wang L. Harding P. Xu W. Inverse correlation between plasma adropin and et-1 levels in essential hypertension: A cross- sectional study. Medicine 2015 94 40 e1712 10.1097/MD.0000000000001712 26448026
    [Google Scholar]
  25. Mayyas F. Saadeh N. Al-Muqbel K. Van Wagoner D.R. Plasma endothelin-1 levels are increased in atrial fibrillation patients with hyperthyroidism. PLoS One 2018 13 12 e0208206 10.1371/journal.pone.0208206 30513109
    [Google Scholar]
  26. Kostov K. Blazhev A. Circulating levels of endothelin-1 and big endothelin-1 in patients with essential hypertension. Pathophysiology. 2021 28 4 489 495 10.3390/pathophysiology28040031 35366246
    [Google Scholar]
  27. Salvi E. Kutalik Z. Glorioso N. Benaglio P. Frau F. Kuznetsova T. Arima H. Hoggart C. Tichet J. Nikitin Y.P. Conti C. Seidlerova J. Tikhonoff V. Stolarz-Skrzypek K. Johnson T. Devos N. Zagato L. Guarrera S. Zaninello R. Calabria A. Stancanelli B. Troffa C. Thijs L. Rizzi F. Simonova G. Lupoli S. Argiolas G. Braga D. D’Alessio M.C. Ortu M.F. Ricceri F. Mercurio M. Descombes P. Marconi M. Chalmers J. Harrap S. Filipovsky J. Bochud M. Iacoviello L. Ellis J. Stanton A.V. Laan M. Padmanabhan S. Dominiczak A.F. Samani N.J. Melander O. Jeunemaitre X. Manunta P. Shabo A. Vineis P. Cappuccio F.P. Caulfield M.J. Matullo G. Rivolta C. Munroe P.B. Barlassina C. Staessen J.A. Beckmann J.S. Cusi D. Genomewide association study using a high-density single nucleotide polymorphism array and case-control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial NO synthase. Hypertension. 2012 59 2 248 255 10.1161/HYPERTENSIONAHA.111.181990 22184326
    [Google Scholar]
  28. Shichiri M. Hirata Y. Ando K. Emori T. Ohta K. Kimoto S. Ogura M. Inoue A. Marumo F. Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 1990 15 5 493 496 10.1161/01.HYP.15.5.493 2185151
    [Google Scholar]
  29. Stewart D.J. Levy R.D. Cernacek P. Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann. Intern. Med. 1991 114 6 464 469 10.7326/0003‑4819‑114‑6‑464 1994793
    [Google Scholar]
  30. Chang H. Wu G.J. Wang S.M. Hung C.R. Plasma endothelin levels and surgically correctable pulmonary hypertension. Ann. Thorac. Surg. 1993 55 2 450 458 10.1016/0003‑4975(93)91018‑I 8431058
    [Google Scholar]
  31. Hiramoto Y. Shioyama W. Kuroda T. Masaki M. Sugiyama S. Okamoto K. Hirota H. Fujio Y. Hori M. Yamauchi-Takihara K. Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension. Circ. J. 2007 71 3 367 369 10.1253/circj.71.367 17322637
    [Google Scholar]
  32. Yoshibayashi M. Nishioka K. Nakao K. Saito Y. Matsumura M. Ueda T. Temma S. Shirakami G. Imura H. Mikawa H. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation 1991 84 6 2280 2285 10.1161/01.CIR.84.6.2280 1959183
    [Google Scholar]
  33. Lerman A. Edwards B.S. Hallett J.W. Heublein D.M. Sandberg S.M. Burnett J.C. Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N. Engl. J. Med. 1991 325 14 997 1001 10.1056/NEJM199110033251404 1886637
    [Google Scholar]
  34. Minami S. Yamano S. Yamamoto Y. Sasaki R. Nakashima T. Takaoka M. Hashimoto T. Associations of plasma endothelin concentration with carotid atherosclerosis and asymptomatic cerebrovascular lesions in patients with essential hypertension. Hypertens. Res. 2001 24 6 663 670 10.1291/hypres.24.663 11768725
    [Google Scholar]
  35. de Haro Miralles J. Gónzalez A.F. Varela Casariego C. García F.A. Onset of peripheral arterial disease: Role of endothelin in endothelial dysfunction. Interact. Cardiovasc. Thorac. Surg. 2010 10 5 760 765 10.1510/icvts.2009.227967 20154344
    [Google Scholar]
  36. Arendt R.M. Wilbert-Lampen U. Heucke L. Schmoeckel M. Sühler K. Richter W.O. Increased endothelin plasma concentrations in patients with coronary artery disease or hyperlipoproteinemia without coronary events. Res. Exp. Med. 1993 193 1 225 230 10.1007/BF02576230 8235075
    [Google Scholar]
  37. Naya M. Aikawa T. Manabe O. Obara M. Koyanagawa K. Katoh C. Tamaki N. Elevated serum endothelin-1 is an independent predictor of coronary microvascular dysfunction in non-obstructive territories in patients with coronary artery disease. Heart Vessels. 2021 36 7 917 923 10.1007/s00380‑020‑01767‑x 33484293
    [Google Scholar]
  38. Drakopoulos A. Goumenos D.S. Vlachojannis J.G. Tsakas S. Endothelin receptors in the kidney of patients with proteinuric and non-proteinuric nephropathies. Ren. Fail. 2006 28 6 461 467 10.1080/08860220600778944 16928614
    [Google Scholar]
  39. Dolinina J. Rippe A. Öberg C.M. Sustained, delayed, and small increments in glomerular permeability to macromolecules during systemic ET-1 infusion mediated via the ETAreceptor. Am. J. Physiol. Renal Physiol. 2019 316 6 F1173 F1179 10.1152/ajprenal.00040.2019 30864842
    [Google Scholar]
  40. Predel H.G. Meyer-Lehnert H. Bäcker A. Stelkens H. Kramer H.J. Plasma concentrations of endothelin in patients with abnormal vascular reactivity. Life Sci. 1990 47 20 1837 1843 10.1016/0024‑3205(90)90286‑Z 2259271
    [Google Scholar]
  41. Farrah T.E. Anand A. Gallacher P.J. Kimmitt R. Carter E. Dear J.W. Mills N.L. Webb D.J. Dhaun N. Endothelin receptor antagonism improves lipid profiles and lowers PCSK9 (proprotein convertase subtilisin/kexin type 9) in patients with chronic kidney disease. Hypertension. 2019 74 2 323 330 10.1161/HYPERTENSIONAHA.119.12919 31177906
    [Google Scholar]
  42. Elnaga A.A.A. Alsaied M.A. Elettreby A.M. Ramadan A. Abouzid M. Shetta R. Al-Ajlouni Y.A. Safety and efficacy of sparsentan versus irbesartan in focal segmental glomerulosclerosis and IgA nephropathy: A systematic review and meta-analysis of randomized controlled trials. BMC Nephrol. 2024 25 1 316 10.1186/s12882‑024‑03713‑9 39333921
    [Google Scholar]
  43. McMurray J.J. Ray S.G. Abdullah I. Dargie H.J. Morton J.J. Plasma endothelin in chronic heart failure. Circulation 1992 85 4 1374 1379 10.1161/01.CIR.85.4.1374 1532540
    [Google Scholar]
  44. Parker J.D. Thiessen J.J. Increased endothelin-1 production in patients with chronic heart failure. Am. J. Physiol. Heart Circ. Physiol. 2004 286 3 H1141 H1145 10.1152/ajpheart.00239.2001 14766679
    [Google Scholar]
  45. Sikkeland L.I.B. Dahl C.P. Ueland T. Andreassen A.K. Gude E. Edvardsen T. Holm T. Yndestad A. Gullestad L. Kongerud J. Aukrust P. Øie E. Increased levels of inflammatory cytokines and endothelin-1 in alveolar macrophages from patients with chronic heart failure. PLoS One 2012 7 5 e36815 10.1371/journal.pone.0036815 22615818
    [Google Scholar]
  46. Rodeheffer R.J. Lerman A. Heublein D.M. Burnett J.C. Jr. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin. Proc. 1992 67 8 719 724 10.1016/S0025‑6196(12)60795‑2 1434909
    [Google Scholar]
  47. Wei C.M. Lerman A. Rodeheffer R.J. McGregor C.G. Brandt R.R. Wright S. Heublein D.M. Kao P.C. Edwards W.D. Burnett J.C. Jr. Endothelin in human congestive heart failure. Circulation 1994 89 4 1580 1586 10.1161/01.CIR.89.4.1580 8149524
    [Google Scholar]
  48. Galatius-Jensen S. Wroblewski H. Emmeluth C. Bie P. Haunsø S. Kastrup J. Plasma endothelin in congestive heart failure: A predictor of cardiac death? J. Card. Fail. 1996 2 2 71 76 10.1016/S1071‑9164(96)80025‑X 8798108
    [Google Scholar]
  49. Kinugawa T. Kato M. Ogino K. Osaki S. Igawa O. Hisatome I. Shigemasa C. Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure. J. Card. Fail. 2003 9 4 318 324 10.1054/jcaf.2003.39 13680553
    [Google Scholar]
  50. Stewart D.J. Kubac G. Costello K.B. Cernacek P. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J. Am. Coll. Cardiol. 1991 18 1 38 43 10.1016/S0735‑1097(10)80214‑1 2050938
    [Google Scholar]
  51. Khan I.A. Role of endothelin-1 in acute myocardial infarction. Chest. 2005 127 5 1474 1476 10.1378/chest.127.5.1474 15888812
    [Google Scholar]
  52. Antonopoulos A. Kyriacou C. Kazianis G. Significance of endothelin-1 in myocardial infarction. Hellenic J. Cardiol. 2007 48 3 161 164 17629179
    [Google Scholar]
  53. Yip H.K. Wu C.J. Chang H.W. Yang C.H. Yu T.H. Chen Y.H. Hang C.L. Prognostic value of circulating levels of endothelin-1 in patients after acute myocardial infarction undergoing primary coronary angioplasty. Chest 2005 127 5 1491 1497 10.1378/chest.127.5.1491 15888819
    [Google Scholar]
  54. Kolettis T.M. Barton M. Langleben D. Matsumura Y. Endothelin in coronary artery disease and myocardial infarction. Cardiol. Rev. 2013 21 5 249 256 10.1097/CRD.0b013e318283f65a 23422018
    [Google Scholar]
  55. Ziv I. Fleminger G. Djaldetti R. Achiron A. Melamed E. Sokolovsky M. Increased plasma endothelin-1 in acute ischemic stroke. Stroke 1992 23 7 1014 1016 10.1161/01.STR.23.7.1014 1615534
    [Google Scholar]
  56. Sapira V. Cojocaru I.M. Lilios G. Grigorian M. Cojocaru M. Study of endothelin-1 in acute ischemic stroke. Rom. J. Intern. Med. 2010 48 4 329 332 21528761
    [Google Scholar]
  57. Alioğlu Z. Bülbül I. Örem A. Özmenoğlu M. Vanizor B. Boz C. Increased plasma endothelin-1 levels in patients with intracerebral hemorrhage. J. Stroke Cerebrovasc. Dis. 2000 9 4 176 180 10.1053/jscd.2000.7231 24192024
    [Google Scholar]
  58. Nusrat S. Khan M.S. Fazili J. Madhoun M.F. Cirrhosis and its complications: Evidence based treatment. World J. Gastroenterol. 2014 20 18 5442 5460 10.3748/wjg.v20.i18.5442 24833875
    [Google Scholar]
  59. Uchihara M. Izumi N. Sato C. Marumo F. Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis. Hepatology. 1992 16 1 95 99 10.1002/hep.1840160117 1535610
    [Google Scholar]
  60. Uchida Y. Watanabe M. Plasma endothelin-1 concentrations are elevated in acute hepatitis and liver cirrhosis but not in chronic hepatitis. Gastroenterol. Jpn. 1993 28 5 666 672 10.1007/BF02806347 8224617
    [Google Scholar]
  61. Gerbes A.L. Møller S. Gülberg V. Henriksen J.H. Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: Role of splanchnic and renal passage and liver function. Hepatology 1995 21 3 735 739 7875671
    [Google Scholar]
  62. Bernardi M. Gülberg V. Colantoni A. Trevisani F. Gasbarrini A. Grebes A.L. Plasma endothelin-1 and -3 in cirrhosis: Relationship with systemic hemodynamics, renal function and neurohumoral systems. J. Hepatol. 1996 24 2 161 168 10.1016/S0168‑8278(96)80025‑0 8907569
    [Google Scholar]
  63. Asbert M. Ginès A. Ginès P. Jiménez W. Clària J. Saló J. Arroyo V. Rivera F. Rodés J. Circulating levels of endothelin in cirrhosis. Gastroenterology 1993 104 5 1485 1491 10.1016/0016‑5085(93)90360‑O 8482460
    [Google Scholar]
  64. Milnerowicz S. Milnerowicz H. Nabzdyk S. Jabłonowska M. Grabowski K. Taboła R. Plasma endothelin-1 levels in pancreatic inflammations. Adv. Clin. Exp. Med. 2013 22 3 361 368 23828677
    [Google Scholar]
  65. Bennett J. Cooper D. Balakrishnan A. Rhodes M. Lewis M. Is there a role for serum endothelin in predicting the severity of acute pancreatitis? Hepatobiliary Pancreat. Dis. Int. 2006 5 2 290 293 16698594
    [Google Scholar]
  66. Zeng X.H. Zhu S.Q. Zhang X.M. Luo W.J. Li S.W. Plasma endothelin and nitric oxide levels in patients with acute pancreatitis. Hepatobiliary Pancreat. Dis. Int. 2002 1 1 140 142 14607644
    [Google Scholar]
  67. Haufschild T. Shaw S.G. Kesselring J. Flammer J. Increased endothelin-1 plasma levels in patients with multiple sclerosis. J. Neuroophthalmol. 2001 21 1 37 38 10.1097/00041327‑200103000‑00011 11315981
    [Google Scholar]
  68. Morelli S. Ferri C. Di Francesco L. Baldoncini R. Carlesimo M. Bottoni U. Properzi G. Santucci A. Plasma endothelin-1 levels in patients with systemic sclerosis: Influence of pulmonary or systemic arterial hypertension. Ann. Rheum. Dis. 1995 54 9 730 734 10.1136/ard.54.9.730 7495344
    [Google Scholar]
  69. Letizia C. Boirivant M. De Toma G. Cerci S. Subioli S. Scuro L. Ferrari P. Pallone F. Plasma levels of endothelin-1 in patients with Crohn’s disease and ulcerative colitis. Ital. J. Gastroenterol. Hepatol. 1998 30 3 266 269 9759593
    [Google Scholar]
  70. Torres J. Mehandru S. Colombel J.F. Peyrin-Biroulet L. Crohn’s disease. Lancet 2017 389 10080 1741 1755 10.1016/S0140‑6736(16)31711‑1 27914655
    [Google Scholar]
  71. Julkunen H. Saijonmaa O. Grönhagen-Riska C. Teppo A.M. Fyhrquist F. Raised plasma concentrations of endothelin-1 in systemic lupus erythematosus. Ann. Rheum. Dis. 1991 50 7 526 527 10.1136/ard.50.7.526‑c 1877866
    [Google Scholar]
  72. Yamane K. Kashiwagi H. Suzuki N. Miyauchi T. Yanagisawa M. Goto K. Masaki T. Elevated plasma levels of endothelin-1 in systemic sclerosis. Arthritis Rheum. 1991 34 2 243 244 10.1002/art.1780340220 1994925
    [Google Scholar]
  73. Miyasaka N. Hirata Y. Ando K. Sato K. Morita H. Shichiri M. Kanno K. Tomita K. Marumo F. Increased production of endothelin-1 in patients with inflammatory arthritides. Arthritis Rheum. 1992 35 4 397 400 10.1002/art.1780350406 1567488
    [Google Scholar]
  74. Pache M. Schwarz H.A. Kaiser H.J. Wüest P. Klöti M. Dubler B. Flammer J. Elevated plasma endothelin-1 levels and vascular dysregulation in patients with rheumatoid arthritis. Med. Sci. Monit. 2002 8 9 CR616 CR619 12218941
    [Google Scholar]
  75. Zachariae H. Heickendorff L. Bjerring P. Plasma endothelin in psoriasis: Possible relations to therapy and toxicity. Acta Derm. Venereol. 1996 76 6 442 443 10.2340/0001555576442443 8982406
    [Google Scholar]
  76. Turgunova L. Mekhantseva I. Laryushina Y. Alina A. Bacheva I. Zhumadilova Z. Turmukhambetova A. The association of endothelin-1 with early and long-term mortality in COVID-19. J. Pers. Med. 2023 13 11 1558 10.3390/jpm13111558 38003873
    [Google Scholar]
  77. Willems L.H. Nagy M. ten Cate H. Spronk H.M.H. Groh L.A. Leentjens J. Janssen N.A.F. Netea M.G. Thijssen D.H.J. Hannink G. van Petersen A.S. Warlé M.C. Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19. Thromb. Res. 2022 209 106 114 10.1016/j.thromres.2021.11.027 34922160
    [Google Scholar]
  78. Jacobs L.M.C. Wintjens M.S.J.N. Nagy M. Willems L. ten Cate H. Spronk H.M.H. van Kuijk S.M.J. Ghossein-Doha C. Netea M.G. Groh L.A. van Petersen A.S. Warlé M.C. Biomarkers of sustained systemic inflammation and microvascular dysfunction associated with post-COVID-19 condition symptoms at 24 months after SARS-CoV-2-infection. Front. Immunol. 2023 14 1182182 10.3389/fimmu.2023.1182182 37868959
    [Google Scholar]
  79. Liu T. Li X. Liu D. Liu S. Dong M. Increased serum CA125 II, but not CEA,CA19-9,AFP or CA72-4 in colon cancer compared to rectal cancer. Br. J. Biomed. Sci. 2021 78 4 218 220 10.1080/09674845.2020.1868685 33393429
    [Google Scholar]
  80. Sproston N.R. Ashworth J.J. Role of C-reactive protein at sites of inflammation and infection. Front. Immunol. 2018 9 9 754 10.3389/fimmu.2018.00754 29706967
    [Google Scholar]
  81. Lapić I. Padoan A. Bozzato D. Plebani M. Erythrocyte sedimentation rate and C-reactive protein in acute inflammation. Am. J. Clin. Pathol. 2020 153 1 14 29 10.1093/ajcp/aqz142 31598629
    [Google Scholar]
  82. Rizo-Téllez S.A. Sekheri M. Filep J.G. C-reactive protein: A target for therapy to reduce inflammation. Front. Immunol. 2023 14 14 1237729 10.3389/fimmu.2023.1237729 37564640
    [Google Scholar]
  83. Rubanyi G.M. Botelho L.H.P. Endothelins. FASEB J. 1991 5 12 2713 2720 10.1096/fasebj.5.12.1916094 1916094
    [Google Scholar]
  84. Neylon C.B. Vascular biology of endothelin signal transduction. Clin. Exp. Pharmacol. Physiol. 1999 26 2 149 153 10.1046/j.1440‑1681.1999.03013.x 10065337
    [Google Scholar]
  85. Hasdai D. Kornowski R. Battler A. Endothelin and myocardial ischemia. Cardiovasc. Drugs Ther. 1994 8 4 589 599 10.1007/BF00877413 7848895
    [Google Scholar]
  86. Li P. Schmidt I.M. Sabbisetti V. Tio M.C. Opotowsky A.R. Waikar S.S. Plasma endothelin-1 and risk of death and hospitalization in patients undergoing maintenance hemodialysis. Clin. J. Am. Soc. Nephrol. 2020 15 6 784 793 10.2215/CJN.11130919 32381583
    [Google Scholar]
  87. Opgenorth T.J. Endothelin receptor antagonism. Adv. Pharmacol. 1995 33 1 65 10.1016/S1054‑3589(08)60665‑1 7495668
    [Google Scholar]
  88. Kiowski W. Kim J. Oechslin E. Sütsch G. Hunziker P. Müller P. Bertel O. Schmitt R. Jones R. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995 346 8977 732 736 10.1016/S0140‑6736(95)91504‑4 7658874
    [Google Scholar]
  89. Benigni A. Remuzzi G. Endothelin antagonists. Lancet 1999 353 9147 133 138 10.1016/S0140‑6736(98)09423‑9 10023915
    [Google Scholar]
  90. Demattia G. Cassonefaldetta M. Bellini C. Bravi M. Laurenti O. Baldoncini R. Santucci A. Ferri C. Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy. Am. J. Hypertens. 1998 11 8 983 988 10.1016/S0895‑7061(98)00094‑6 9715792
    [Google Scholar]
  91. Roux S. Rubin L.J. Bosentan: A dual endothelin receptor antagonist. Expert. Opin. Investig. Drugs. 2002 11 7 991 1002 10.1517/13543784.11.7.991 12084009
    [Google Scholar]
  92. Klinger J. Ambrisentan for the treatment of pulmonary arterial hypertension. Drug Des. Devel. Ther. 2008 265 265 10.2147/DDDT.S3057
    [Google Scholar]
  93. Çelik G. Karabiyikoğlu G. Local and peripheral plasma endothelin-1 in pulmonary hypertension secondary to chronic obstructive pulmonary disease. Respiration. 1998 65 4 289 294 10.1159/000029278 9730795
    [Google Scholar]
  94. Fagan K.A. McMurtry I.F. Rodman D.M. Role of endothelin-1 in lung disease. Respir. Res. 2001 2 2 90 101 10.1186/rr44 11686871
    [Google Scholar]
  95. Nova A. Sibai B.M. Barton J.R. Mercer B.M. Mitchell M.D. Maternal plasma level of endothelin is increased in preeclampsia. Am. J. Obstet. Gynecol. 1991 165 3 724 727 10.1016/0002‑9378(91)90317‑K 1892201
    [Google Scholar]
  96. Best R.M. Hayes R. Chakravarthy U. Archer D.B. Hadden D.R. Plasma levels of endothelin-1 in diabetic retinopathy in pregnancy. Eye 1999 13 2 179 182 10.1038/eye.1999.47 10450378
    [Google Scholar]
  97. Khedun S.M. Naicker T. Moodley J. Endothelin-1 activity in pregnancy. J. Obstet. Gynaecol. 2002 22 6 590 593 10.1080/0144361021000020321 12554242
    [Google Scholar]
  98. Wollesen F. Berglund L. Berne C. Plasma endothelin-1 and total insulin exposure in diabetes mellitus. Clin. Sci. 1999 97 2 149 156 10.1042/cs0970149 10409469
    [Google Scholar]
  99. Tomoda H. Plasma endothelin-1 in acute myocardial infarction with heart failure. Am. Heart J. 1993 125 3 667 672 10.1016/0002‑8703(93)90155‑3 8438694
    [Google Scholar]
  100. Haynes W.G. Wayne Hamer D. Robertson C.E. Webb D.J. Plasma endothelin following cardiac arrest: Differences between survivors and non-survivors. Resuscitation 1994 27 2 117 122 10.1016/0300‑9572(94)90003‑5 8029532
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673377544250714073536
Loading
Endothelin: A Potential Universal Systemic Biomarker
Bentham Science Publishers ; https://doi.org/10.2174/0109298673377544250714073536
/content/journals/cmc/10.2174/0109298673377544250714073536
/content/journals/cmc/10.2174/0109298673377544250714073536
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Endothelin-1 ; liver failure ; heart failure ; biomarker ; autoimmunity ; chronic kidney disease ; hypertension

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test